In Phase A, contributors will acquire unique doses and schedules of oral ABBV-744 tablet to recognize Risk-free dosing routine. Supplemental individuals will probably be enrolled with the identified monotherapy dosign regimen. In Segment B, individuals will acquire oral ruxolitinib and ABBV-744 is going to be offered as "increase-on" therapy. In https://abbv-744-combination-ther57901.activablog.com/31349678/how-much-you-need-to-expect-you-ll-pay-for-a-good-abbv-744-combination-therapy-with-chemotherapy